Something big is looming in Harbinger Health’s future, and the company has now secured a sizable funding round to help get it there. Harbinger is developing a suite of liquid biopsy tests plus an accompanying software program to analyze the collected blood samples in search of the earliest signs of cancer. Per an announcement Thursday, the company has closed a series B financing with a total of $140 million raised to advance the development of the screening platform.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,